QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 cyclacel-pharmaceuticals-q2-2024-gaap-eps-072-beats-144-estimate-sales-400k-miss-3000k-estimate

Cyclacel Pharmaceuticals (NASDAQ:CYCC) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate...

Core News & Articles

 - Novel CDK2/9 inhibitor fadraciclib induces anaphase catastrophe, a novel cancer-specific mechanism of action -BERKELEY HEIGH...

Core News & Articles

- Clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing proof of concept study i...

 cyclacel-pharmaceuticals-q1-eps-227-beats-474-estimate-sales-2900k

Cyclacel Pharmaceuticals (NASDAQ:CYCC) reported quarterly losses of $(2.27) per share which beat the analyst consensus estimate...

 roth-mkm-maintains-buy-on-cyclacel-pharmaceuticals-lowers-price-target-to-11

Roth MKM analyst Jonathan Aschoff maintains Cyclacel Pharmaceuticals (NASDAQ:CYCC) with a Buy and lowers the price target fr...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION